Lexaria Bioscience Corp Stock Today
| LEXXW Stock | USD 0.38 0.06 13.41% |
Performance0 of 100
| Odds Of DistressOver 54
|
Lexaria Bioscience is selling for under 0.38100001 as of the 1st of February 2025; that is 13.41% down since the beginning of the trading day. The stock's lowest day price was 0.38. Lexaria Bioscience has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 5th of August 2024 and ending today, the 1st of February 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of January 2021 | Category Healthcare | Classification Health Care |
Lexaria Bioscience Corp. operates in the drug delivery platform business. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. Lexaria Bioscience is traded on NASDAQ Exchange in the United States. More on Lexaria Bioscience Corp
Moving against Lexaria Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Lexaria Stock Highlights
| President Director | John MSc | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Materials, Materials (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexaria Bioscience can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Lexaria Bioscience's financial leverage. It provides some insight into what part of Lexaria Bioscience's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lexaria Bioscience Corp (LEXXW) is traded on NASDAQ Exchange in USA. It is located in 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7 and employs 5 people. Lexaria Bioscience is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 33.79 M. Lexaria Bioscience Corp classifies itself under Biotechnology sector and is part of Health Care industry.
Lexaria Bioscience Corp has accumulated about 1.31 M in cash with (4.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.44, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Lexaria Bioscience Probability Of Bankruptcy
Lexaria Bioscience Historical Income Statement
Lexaria Stock Against Markets
Lexaria Bioscience Corporate Management
| Christopher Bunka | Chairman CEO | Profile | |
| Vanessa Carle | Head Legal | Profile | |
| Philip Ainslie | Advisor Consultant | Profile | |
| Nelson CPA | Chief Officer | Profile | |
| Richard Christopher | Chief Officer | Profile | |
| Michael CPA | Chief Officer | Profile |
Additional Tools for Lexaria Stock Analysis
When running Lexaria Bioscience's price analysis, check to measure Lexaria Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lexaria Bioscience is operating at the current time. Most of Lexaria Bioscience's value examination focuses on studying past and present price action to predict the probability of Lexaria Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lexaria Bioscience's price. Additionally, you may evaluate how the addition of Lexaria Bioscience to your portfolios can decrease your overall portfolio volatility.